Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drotrecogin alfa.

Michael J Raggio1, Peter E Morris

  • 1Pulmonary and Critical Care Medicine, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA.

Drugs of Today (Barcelona, Spain : 1998)
|September 7, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Electrical Impedance Tomography in Nonintubated Patients: Advancing Validation and Defining Clinical Value.

Respiratory care·2026
Same author

An improved analytic workflow for serum mtDNA DAMP abundance, fragmentation and heteroplasmic variants: a retrospective analysis of acute respiratory failure patients.

Scientific reports·2026
Same author

A proteomics and redox proteomics approach to understanding ARDS heterogeneity.

Scientific reports·2026
Same author

Metabolomic Biomarkers Predict Long-term Physical Function in Survivors of Acute Respiratory Failure.

Research square·2025
Same author

Serum mtDNA DAMP abundance, fragmentation and heteroplasmic variants associate with Acute Respiratory Failure outcome: A secondary analysis of study NCT00976833.

medRxiv : the preprint server for health sciences·2025
Same author

Metabolomic biomarkers predict long-term physical function in survivors of acute respiratory failure.

Respiratory research·2025
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Drotrecogin alfa (activated), a protein therapy, reduced mortality in severe sepsis patients. This treatment targets the complex interplay between coagulation and inflammation in sepsis.

Area of Science:

  • Biochemistry
  • Critical Care Medicine
  • Hematology

Background:

  • Severe sepsis involves complex interactions between coagulation and inflammation pathways.
  • Thrombin plays a key role in thrombus formation and activating inflammatory cells.
  • Patients with severe sepsis often exhibit a coagulopathic state with low protein C levels.

Purpose of the Study:

  • To evaluate the efficacy of drotrecogin alfa (activated) in patients with severe sepsis.
  • To investigate the role of activated protein C in modulating coagulation and inflammation during sepsis.

Main Methods:

  • Intravenous administration of drotrecogin alfa (activated) as a continuous, weight-based dose.
  • Phase III clinical trial design to assess patient outcomes.

Related Experiment Videos

Main Results:

  • A significant reduction in mortality was observed in severe sepsis patients treated with drotrecogin alfa (activated).
  • Activated protein C demonstrated potential to inhibit microvascular thrombi and promote fibrinolysis.

Conclusions:

  • Drotrecogin alfa (activated) is an effective therapeutic agent for reducing mortality in severe sepsis.
  • Targeting the coagulation and inflammation pathways with activated protein C offers a promising strategy for sepsis management.